Showing results (361-370 of 461) with videos related to

Sort By:
Pageof 47
Wiener Klinische Wochenschrift|September 20, 2023
[General recommendations for the management of glomerular diseases-2023]Martin Windpessl, Philipp Gauckler, Emanuel Zitt, et al.
American Journal of Hematology|September 11, 2002
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemiaMarco Ruggeri, Heinz Gisslinger, Alberto Tosetto, et al.
Annals of Hematology|May 1, 2016
Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopeniaAnn Janssens, Francesco Rodeghiero, David Anderson, et al.
Wiener Klinische Wochenschrift|November 4, 2015
[Treatment of haemophilia in Austria]Ingrid Pabinger, Max Heistinger, Wolfgang Muntean, et al.
Scientific Reports|February 5, 2021
The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patientsKatarina D Kovacevic, Stefan Greisenegger, Agnes Langer, et al.
Journal of Thrombosis and Haemostasis : JTH|August 24, 2025
External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: Results from the RIETE registryTimothy Hoberstorfer, Stephan Nopp, Daniel Steiner, et al.
The European Respiratory Journal|December 11, 2020
Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolismMarisa Peris, Juan J López-Nuñez, Ana Maestre, et al.
JACC. Advances|August 23, 2025
Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry AnalysisJavier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, et al.
Thrombosis Research|August 24, 2020
Von Willebrand Factor and ADAMTS13 and long-term outcomes in patients undergoing percutaneous coronary interventionMaximilian Tscharre, Ioannis Tentzeris, Birgit Vogel, et al.
British Journal of Haematology|February 23, 2019
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studiesDavid J Kuter, Adrian Newland, Beng H Chong, et al.
Pageof 47